Description
| Product Name | CAT.No | Size |
| Tumour Marker Control Level 1 | BXC0792A | 5 x 2ml |
| Tumour Marker Control Level 2 | BXC0792B | 5 x 2ml |
| Tumour Marker Control Level 3 | BXC0792C | 5 x 2ml |
| Tumour Marker Control Set Level 1 – 3 | BXC0793A | 3 x 1 x 2ml |
Product Description
The Biorex Diagnostics Tumour Marker Control kits provide human serum–based, ready-to-use materials for precise quality control of multiple oncology-related assays, including AFP, CEA, CA-125, CA 19-9, CA 15-3, Ferritin, ß2-Microglobulin, PSA, FßhCG, and Thyroglobulin. Designed for use in clinical laboratories, these controls enable accurate monitoring of assay performance across low, normal, and high concentration ranges. By closely mimicking patient samples, the kits ensure excellent reproducibility and analytical reliability, supporting early cancer detection, therapy monitoring, and effective patient management. Routine use helps laboratories maintain consistent analytical performance, identify shifts in assay accuracy at an early stage, and provide clinicians with dependable data for informed decision-making.
Key Features
- Human Serum–Based Materials – Replicates patient sample characteristics, ensuring clinically relevant quality control and reliable performance.
- Multiple Control Levels – Low, normal, and high concentrations allow comprehensive assessment of assay accuracy across clinically significant ranges.
- Liquid-Stable, Ready-to-Use Format – Reduces preparation time, minimises handling errors, and delivers consistent, reproducible results.
- Wide Analyser Compatibility – Suitable for immunoassay platforms on major automated and semi-automated systems, offering flexibility for diverse laboratory workflows.
- Precision and Accuracy Monitoring – Enables continuous evaluation of reproducibility across runs, instruments, and reagent lots.
The Biorex Diagnostics Tumour Marker Control kits are essential for laboratories performing tumour marker testing, providing dependable quality control that strengthens confidence in reported results. Their implementation supports standardisation between platforms, assists with regulatory compliance to ISO 15189, CAP, and CLIA requirements, and improves long-term assay stability. By ensuring accurate and consistent measurement of critical cancer-related analytes, these controls contribute to reliable diagnosis, prognosis assessment, and treatment evaluation. The result is enhanced diagnostic confidence, improved workflow efficiency, and consistently high analytical performance for laboratories focused on oncology testing.
Contact Us for more information.